

Plant & Regd. Office: Plot No. B-31, M.I.D.C. - Mahad, Taluka-Mahad, Dist. Raigad - 402 302. Maharashtra, India • Mob. : 9869234017

CIN No.: L24110MH1988PLC049683 Web.: www.caprolactam.co.in Email: caprolactam@gmail.com

14th August, 2025

The Deputy Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai – 400001.

Scrip Code: 507486 (BSE)

Dear Sir,

Subject: Submission of the unaudited financial results for Quarter ended, 30th June, 2025

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025 along with Limited Review Report submitted by the Statutory Auditors of the Company. The above financial results were upon recommendation of the Audit Committee approved by the Board of Directors at its meeting held on August 14th, 2025. The meeting of the Board of Directors of the Company commenced at 4:00 p.m. and concluded at 5:00 p.m.

Considered and approved Others Agenda items in Board Meeting: -

- Considered, approved and appointed, Mr. Rahul shivji Gori as the Scrutinizer for scrutinizing the E-Voting process for the 36th Annual General Meeting of the Company as per the provisions of Companies Act, 2013 and other applicable provisions, if any, and rules made there under.
- 2. Considered and approved the Director's Report along with Annexures for the financial year ended March 31, 2025 as per the provisions of Companies Act, 2013 and other applicable provisions and rule made there under;
- 3. Considered and approved the draft Notice of the 36th Annual General Meeting of the Company scheduled to be held on Thursday, September 25, 2025 at 10:30 A.M at to incorporate above mentioned matters for the approval of the Shareholders.
- Considered and fixed Record date for the purpose of 36th Annual General Meeting and decided the E- voting period mentioned below:



Plant & Regd. Office: Plot No. B-31, M.I.D.C. - Mahad, Taluka-Mahad, Dist. Raigad - 402 302. Maharashtra, India • Mob. : 9869234017 CIN No. : L24110MH1988PLC049683

Web.: www.caprolactam.co.in Email: caprolactam@gmail.com

Sr No.	Particulars	Date		
1	Cut-off date for determining the Members who are entitled to vote on the resolutions set forth in this Notice.	September 17, 2025		
2	E-Voting Period	(9.00 A.M) Friday, September 20, 2025 to (5.00 P.M.) Wednesday, September 24, 20		

 Considered and approved Appointment of Purva Sharegistry (India) Pvt. Ltd. (CIN: U67120MH1993PTC074079) for e voting services for the ensuing Annual General Meeting.

Kindly take the same on your record.

We request you to inform your members accordingly.

Thanking you.

Yours faithfully,

For Caprolactam Chemicals Limited

Siddharth Shankarlal Bhanushali

Director

DIN: 01721586



PULINDRA PATEL & CO. CHARTERED ACCOUNTANTS

Office No. A-1004, Paras Business Center, Near Borivali Station East, Kasturba Road No.1, Borivali (East), Mumbai $-66,\,$

Office (Tel) + 022 28069664, 022-22056233, 022-68844594, +91 9322268243, Office (M) + 91 9619908533 Email : caoffice@pulindrapatel.com

Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report to
The Board of Directors,
Caprolactam Chemicals Limited
Plot No. B-31, M.I.D.C.- Mahad,
Taluka – Mahad,
Dist. Raigad – 402302.

We have reviewed the quarterly unaudited standalone financial results of M/S.CAPROLACTAM CHEMICALS LIMITED (the company) for the, Quarter ended June 30, 2025 (the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 as amended ("Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the Statement in accordance with the standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian accounting standards and other accounting principles—generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PULINDRA PATEL & CO. CHARTERED ACCOUNTANTS FIRM REGN. NO. 115187W

Place: Mumbai

Date: 14th August, 2025

PULINDRA PATEL

MEMBERSHIP No. 048991 UDIN: 25048991BMIBKF4547

<u>Caprolactam Chemicals Limited</u> <u>CIN No. L24110MH1988PLC049683</u> <u>UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025</u>

PART I		(Rs. In Lakhs)				
	PARTICULARS	Quarter Ended			Year Ended	
		(Unaudited) 30-06-2025	(Audited) 31-03-2025	(Unaudited) 30-06-2024	(Audited) 31-03-2025	
1	Revenue From Operetion					
	Revenue from Operations	256.47	160.85	112.39	673.96	
	Other Income	0.09	0.17	0.09	0.96	
	Total Income	256.56	161.02	112.48	674.92	
2	Expenses					
(a)	Cost of materials consumed	29.41	-27.67	16.35	53.22	
	Purchase of stock - I trade	4.93	38.94	0.95	84.64	
(c)	Change in inventories of Finished goods, work-in-progress and stock- intrade	3.75	-		(3.75	
(d)	Employee benefits expenses	11.27	10.21	9.67	37.09	
(e)	Finance Costs	18.25	17.61	14.08	62.86	
(f)	Depreciation, depletion and amortisation expenses	38.02	41.23	37.64	158.85	
	Other expenses	102.38	116.66	60.58	350.38	
	Total Expenses	208.01	196.97	139.27	743.29	
3	Profit / (Loss) before tax (1-2)	48.55	(35.96)	(26.79)	(68.37	
4	Tax Expense					
	Current tax	12.23	-	-	-	
	Defered tax	0.11	9.11	(0.16)	2.50	
	Total Tax Expenses	12.34	9.11	(0.16)	2.50	
5	Total Profit/(loss) After Tax (3-4)	36.21	(45.07)	(26.63)	(70.87	
6	Other Comprehensive Income (OCI)				-	
	a) Items That Will Not Be Reclassified To Profit or Loss		(0.96)		(0.96	
	b) Items That Will Be Reclassified To Profit or Loss		-			
7	Total Comprehensive Income/(Loss) for the period (5+6)	36.21	(46.03)	(26.63)	(71.83	
8	Details of equity share capital					
9	Paid-up equity share capital	460.00	460.00	460.00	460.00	
	Face value of equity share capital	10.00	10.00	10.00	10.90	
10	Other Equity					
11	Earnings per share					
12	Earnings per equity share Rs.					
	Basic	0.79	(0.98)	(0.58)	(1.54	
	Diluted	0.79	(0.98)	(0.58)	(1.54	
13	Nominal value of share	10.00	10.00	10.00	10.00	
	Disclosure of notes on finance results					

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th August, 2025 and have been subjected to limited review by the Auditors.

2) These financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3) The Standalone results of the compnay are available on the company's website http://caprolactum.co.in/and also available on the websites of the BSE Ltd. And National Stock Exchange of India Ltd.

4) Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary. Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary.

5) The figures in Rs. Lakhs are rounded off to Two Decimals

Place: Mahad

FOR AND BEHALF OF THE BOARD OF DIRECTORS

Date: 14/08/2025

Mrs. Zaver S Bhanushali

MAHAD CA

Managing Director DIN- 00663374